IFNG and Splenomegaly: However, use of Ruxolitinib, a Janus Kinase (JAK) inhibitor, significantly reduced hypercytokinemia, splenomegaly, and death in an animal model of sHLH to a greater extent compared with administration of IFNγ monoclonal antibodies [26].